Pargluva
Treatment for Diabetes Type 2Bristol-Myers Squibb Provides Regulatory Update for Muraglitazar
PRINCETON, N.J., December 23, 2004 -- Bristol-Myers Squibb Company today announced that the company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for muraglitazar, an investigational agent under development for the treatment of patients with type 2 diabetes. Bristol-Myers Squibb and Merck & Co., Inc. are collaborators in the global development and commercialization of muraglitazar.
Muraglitazar, discovered by Bristol-Myers Squibb, has the potential to be the first in a novel class of drugs known as dual peroxisome proliferator activated receptor (PPAR) agonists to be approved for marketing in the U.S.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
For further information, please visit www.bms.com
Posted: December 2004
Related Articles
- Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment For Type 2 Diabetes - October 27, 2005
- Bristol-Myers Squibb and Merck Joint Statement on Regulatory Status of Pargluva (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes - October 18, 2005
- Bristol-Myers Squibb and Merck Joint Statement on FDA Advisory Committee Vote on Pargluva (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes - September 9, 2005
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
